

TG THERAPEUTICS, INC.  
Form 8-K  
October 27, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 26, 2017

TG Therapeutics, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware 001-32639 36-3898269  
(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)  
of Incorporation)

2 Gansevoort Street, 9th Floor  
New York, New York 10014  
(Address of Principal Executive Offices)

(212) 554-4484  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01. Other Events.

On October 26, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results from the Phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of Multiple Sclerosis (RMS) presented during the 7th JointECTRIMS – ACTRIMS meeting in Paris, France. On October 27, 2017, the Company announced additional results from the Phase 2 multicenter trial of TG-1101 in RMS presented during the 7th JointECTRIMS – ACTRIMS meeting. Copies of the press releases are being filed as Exhibits 99.1 and 99.2 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated October 26, 2017.

99.2 Press Release, dated October 27, 2017.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: October 27, 2017

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer